NorthWest Biotherapeutics Inc (NWBO)

[GoodGuyBill]

Anticipated Milestones and Catalysts in 2015

DCVax-L Phase III Trial Program
• Expansion of the program
• First interim analysis for efficacy – independent DMC review
• Completion of patient recruitment
• Ongoing follow-up on 55 “Information Arm” patients
• Accumulation of “Events” for primary endpoint
DCVax-Direct Trials Program
• Completion of patient treatments and data from Phase I trial
• Obtaining regulatory approvals for expanded DCVax-Direct treatments
• Launch of at least 2 Phase II trials and potential completion of enrollment
DCVax-L Early Access Programs
• UK Early Access to Medicines Scheme (Stage 2/Decision), and Specials Program
• German reimbursement and pricing
• Expansion of manufacturing; distribution/logistics; contracts; gradual ramp-up